Boston Scientific (BSX) Tops Q2 EPS by 4c; offers guidance

Boston Scientific (NYSE: BSX) reported Q2 EPS of $0.62, $0.04 better than the analyst estimate of $0.58. Revenue for the quarter came in at $4.12 billion versus the consensus estimate of $4.02 billion.

GUIDANCE:

Boston Scientific sees Q3 2024 EPS of $0.57-$0.59, versus the consensus of $0.57.

Boston Scientific sees FY2024 EPS of $2.38-$2.42, versus the consensus of $2.33.

For earnings history and earnings-related data on Boston Scientific (BSX) click here.

You May Also Be Interested In

• OpenAI: after the Hugging Face incident, we committed to conducting a much broader review of actions taken by our models
• MARA amends Texas power site purchase agreement, posts $100M deposit
• HeartSciences (HSCS) files $200M mixed shelf